Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBIT Margin: 2021-2025

Historic EBIT Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 13.28%.

  • Kiniksa Pharmaceuticals International's EBIT Margin rose 2189.00% to 13.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.38%, marking a year-over-year increase of 1321.00%. This contributed to the annual value of -10.78% for FY2024, which is 145.00% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EBIT Margin of 13.28% as of Q3 2025, which was up 3.30% from 12.86% recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's EBIT Margin's 5-year high stood at 46.82% during Q3 2022, with a 5-year trough of -253.55% in Q3 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's EBIT Margin averaged around -4.83%, with its median value being -4.41% (2023).
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBIT Margin surged by 30,037bps in 2022 and then plummeted by 6,312bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBIT Margin (Quarterly) stood at -192.75% in 2021, then skyrocketed by 18,867bps to -4.08% in 2022, then skyrocketed by 417bps to 0.10% in 2023, then tumbled by 1,585bps to -15.75% in 2024, then skyrocketed by 2,189bps to 13.28% in 2025.
  • Its last three reported values are 13.28% in Q3 2025, 12.86% for Q2 2025, and 9.63% during Q1 2025.